POPULARITY
Categories
73 episodes with Targeted therapy
54 episodes with Targeted therapy
37 episodes with Targeted therapy
54 episodes with Targeted therapy
72 episodes with Targeted therapy
46 episodes with Targeted therapy
46 episodes with Targeted therapy
37 episodes with Targeted therapy
60 episodes with Targeted therapy
37 episodes with Targeted therapy
37 episodes with Targeted therapy
14 episodes with Targeted therapy
17 episodes with Targeted therapy
13 episodes with Targeted therapy
38 episodes with Targeted therapy
9 episodes with Targeted therapy
8 episodes with Targeted therapy
11 episodes with Targeted therapy
13 episodes with Targeted therapy
10 episodes with Targeted therapy
8 episodes with Targeted therapy
8 episodes with Targeted therapy
13 episodes with Targeted therapy
7 episodes with Targeted therapy
13 episodes with Targeted therapy
6 episodes with Targeted therapy
6 episodes with Targeted therapy
12 episodes with Targeted therapy
6 episodes with Targeted therapy
5 episodes with Targeted therapy
12 episodes with Targeted therapy
4 episodes with Targeted therapy
7 episodes with Targeted therapy
3 episodes with Targeted therapy
3 episodes with Targeted therapy
5 episodes with Targeted therapy
4 episodes with Targeted therapy
12 episodes with Targeted therapy
2 episodes with Targeted therapy
3 episodes with Targeted therapy
3 episodes with Targeted therapy
4 episodes with Targeted therapy
5 episodes with Targeted therapy
3 episodes with Targeted therapy
4 episodes with Targeted therapy
Cancer treatments have changed dramatically over the past decade, but have our dose-finding strategies kept pace? In this episode, I speak with Dr. Ayon Mukherjee, who leads statistical innovation in early oncology development at Eli Lilly. Together, we explore Project Optimus, the FDA initiative that is changing how we think about dose optimization in oncology. Instead of simply finding the highest dose patients can tolerate, Project Optimus encourages us to identify the dose that provides the best balance between efficacy, safety, pharmacokinetics, pharmacodynamics, and long-term tolerability. Ayon explains why the traditional maximum tolerated dose approach worked well for chemotherapy but often falls short for targeted therapies and immunotherapies. We also discuss how statisticians can help lead this transformation by designing better dose optimization studies and collaborating more effectively with clinicians, pharmacologists, and regulators.
Jason Sonners is a chiropractor specializing in functional medicine. He holds a Phd in molecular biology with focus in regenerative medicine. Jason owns and operates 2 clinics with his wife Melissa in the North East. He lives in mMiami, with Melissa and 3 kids, mostly teaching lecturing and consulting for other businesses. In this episode, Dr. Jason Sonners joins Tara to unpack how the health optimization world's obsession with stacking supplements, peptides, cold plunges, and biohacking gadgets can backfire without understanding hormesis, foundational health pillars, and when targeted therapies actually make sense. RESOURCES: Learn more about Jason here: http://hbotusa.com Instagram: @hbotusa Check out Dr. Sonners books here: - Oxygen under Pressure: https://amzn.to/43OS0YM - The Art and Science of Hyperbaric Medicine: https://amzn.to/4jDGa9w Get 10% off Peluva minimalist shoe with coupon code COACHTARA here: http://peluva.com/coachtara CHAPTERS: 0:00 – Intro 1:08 – Meet Dr. Jason Sonners 2:04 – Sponsor: Peluva Shoes Ad 3:51 – Interview Begins: Jason's PhD Journey 4:40 – What Is "Wellness Maxing"? 7:11 – Biohacking's "Be Better" Trap 11:01 – Hawaii's Low-Tech Healthy Elders 12:50 – Bryan Johnson & the Tech Age of Wellness 15:50 – Joshua Tree: Sauna in the Desert 21:00 – Introducing Hormesis 22:02 – Hormesis Explained: The Stress Bell Curve 29:46 – "Just Tell Me What to Do" Trap 31:33 – Foundational vs. Targeted Therapies 32:24 – The Peptide Craze 34:36 – Jason's 5 Foundational Health Pillars 37:01 – Next-Tier Therapies: Contrast, PEMF, Grounding 39:23 – Universal Needs vs. Your Genetics (MTHFR) 41:45 – Host Segment: Coaching, App & Retreats 46:41 – PEMF and Sound as Health Inputs 51:39 – Exercise Variety & Periodization 55:01 – What Worries Jason About Biohacking 57:16 – 3 Sources of Stress: Chemical, Physical, Emotional 1:00:38 – Success Stories: Longevity & Dementia WORK WITH TARA: Are You Looking for Help on Your Wellness Journey? Here's how Tara can help you: TRY TARA'S APP FOR FREE: http://taragarrison.com/app INDIVIDUAL ONLINE COACHING: https://www.taragarrison.com/work-with-me CHECK OUT HIGHER RETREATS: https://www.taragarrison.com/retreats SOCIAL MEDIA: Instagram @coachtaragarrison TikTok @coachtaragarrison Facebook @coachtaragarrison Pinterest @coachtaragarrison INSIDE OUT HEALTH PODCAST SPECIAL OFFERS: ☑️ Upgraded Formulas Hair Test Kit Special Offer: https://bit.ly/3YdMn4Z ☑️ Upgraded Formulas - Get 15% OFF Everything with Coupon Code INSIDEOUT15: https://upgradedformulas.com/INSIDEOUT15 ☑️ Rep Provisions: Vote for the future of food with your dollar! And enjoy a 15% discount while you're at it with Coupon Code COACHTARA: https://bit.ly/3dD4ZSv If you loved this episode, please leave a review! Here's how to do it on Apple Podcasts: Go to Inside Out Health Podcast page: https://podcasts.apple.com/us/podcast/inside-out-health-with-coach-tara-garrison/id1468368093 Scroll down to the 'Ratings & Reviews' section. Tap 'Write a Review' (you may be prompted to log in with your Apple ID). Thank you!
Highlights from the PER® CME activity "Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Justin Gainor, MD; Julia Rotow, MD; and Urs Weber, MD; discuss targeted therapies and immunotherapy to treat advanced non-small cell lung cancer (NSCLC).Earn CME credit by completing the full accredited activity (available through June 29, 2027): https://www.gotoper.com/courses/tumor-board-optimizing-nsclc-careleveraging-the-latest-evidence-on-targeted-therapy-and-immuno-oncology-1fgrThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from BioNTech; Iovance Biotherapeutics, Inc; Lilly; Nuvation Bio; Revolution Medicines, Inc; and Rigel Pharmaceuticals.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.
Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include: Clinical trial updates and discussion of how findings may translate into clinical practice and FDA approvals Treatment sequencing and patient selection Step-up dosing and what to expect in terms of toxicity management when using a GPRC5D-targeted therapy with on-target, off-tumor effects Presenters: Jesus Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FCAP Nason Hollingworth Family Chair in Myeloma Director, Judy and Bernard Briskin Center for Myeloma Professor Hematology/HCT Executive Director of Hematology City of Hope Orange County Irvine, California Content based on an online CME program supported by an educational grant from Johnson & Johnson. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Please visit answersincme.com/REE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Adam Friedman, MD. In this activity, an expert in the management of chronic spontaneous urticaria (CSU) discusses how targeted therapies fit within evolving treatment algorithms and how to integrate them appropriately into clinical practice for improved patient outcomes. Upon completion of this activity, participants should be better able to: Evaluate the rationale for targeted therapies in patients with CSU; Outline the different pathogenic mechanisms in CSU, with a focus on their relationship to type 2 inflammation, and the clinical implications of these different pathways; and Design treatment plans that optimize the use of targeted therapies in CSU, based on the latest evidence and expert insights.
Today I'm delighted to welcome Andy Parker, CEO of Step Pharma.With over 25 years of experience across AstraZeneca, Shire, Zealand Pharma, andventure capital, Andy has led Step Pharma since 2019. The company is pioneeringa targeted approach to cancer and blood disorders by inhibiting the enzymeCTPS1. Their lead candidate, dencatistat, blocks this pathway that certaincancer cells and activated immune cells rely on, while sparing healthy cellsthat use the related CTPS2 enzyme.In this episode, we'll dive into the science behind this mechanism, explore StepPharma's expanding pipeline from lymphomas and solid tumours to essentialthrombocythaemia, and discuss their recent €38 million Series C financing.We'll also look ahead to the future of precision oncology.01:17 Meet Andy Parker06:12 The biotech ecosystem around Geneva07:51 The CTPS1 enzyme and why cancer cells depend on it14:08 Pipeline-in-a-product strategy across three indications20:14 The series C: €38 million raise25:41 Partnering with big pharma: possibilities and limits28:11 The future of precision oncology and metabolic targetingInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Step Pharma and Concr to partner on cancer treatmentStep Pharma moves into oncology clinical trialsStep Pharma announces promising pre-clinical cancer data
Send us Fan MailThere are very few cures for cancers that have already spread. So what does a good outcome actually look like?In this clip from our episode “How Targeted Radiotherapy Is Changing Cancer Care”, host David E. Williams and John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, break down what extending life with quality really means in cancer care, and why giving someone eight more months where they can still live their life is the philosophy driving the work at Ratio Therapeutics.Listen to the full episode here
Send us Fan MailFor decades, cancer treatment has rested on three pillars: surgery, chemotherapy, and external beam radiation. A fourth is now taking shape, and it is drawing billions in investment from some of the largest pharmaceutical companies in the world.John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, joins host David E. Williams to explain how targeted radiotherapeutics pair a tumor-seeking molecule with a radioactive payload, delivering radiation to cancer cells while sparing healthy tissue. He also unpacks what Pluvicto's success in prostate cancer signals for the future of radioligand therapy.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TWT865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until June 7, 2027.Traveling Along the TROP2-Targeted Therapy Pathway in NSCLC: Exploring the Established Role and Expanding Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TWT865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until June 7, 2027.Traveling Along the TROP2-Targeted Therapy Pathway in NSCLC: Exploring the Established Role and Expanding Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TWT865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until June 7, 2027.Traveling Along the TROP2-Targeted Therapy Pathway in NSCLC: Exploring the Established Role and Expanding Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TWT865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until June 7, 2027.Traveling Along the TROP2-Targeted Therapy Pathway in NSCLC: Exploring the Established Role and Expanding Options In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.
How Targeted Therapies Are Reshaping Treatment for Platinum-Resistant Ovarian Cancer Platinum-resistant ovarian cancer remains one of the most challenging settings in oncology, with limited treatment options and historically poor outcomes for many patients. On this episode of Unscripted, the AMCP Podcast, guest host Abby Kim, PharmD, BCOP, Senior Director of Clinical Strategy and Oncology Specialty Solutions at Prime Therapeutics, sits down with Kathleen Moore, MD, Deputy Director of the Fred & Pamela Buffett Cancer Center and Professor of Obstetrics and Gynecology at Nebraska Medicine, to discuss the evolving treatment landscape for recurrent ovarian cancer and the growing role of biomarker-driven care. Dr. Moore explores the history and challenges of treating platinum-resistant disease, reviews the clinical evidence behind ELAHERE®, examines the importance of folate receptor alpha testing, and shares insights on treatment sequencing, patient-reported outcomes, safety and tolerability considerations, and emerging therapies that may further expand options for patients and inform decision-making across managed care. Sponsored by Abbvie, Inc. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen
Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00) Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09) Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56) CME information and select publications
Please visit answersincme.com/860/2026-MC-001755-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Linda Stein Gold, MD and Stephan Weidinger, MD, PhD. In this activity, experts in dermatology discuss the rationale and emerging clinical data supporting the use of OX40/OX40L inhibitors for the treatment of moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting the OX40/OX40L pathway to achieve durable response in the treatment of moderate to severe atopic dermatitis (AD); Review the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD management, including quality of life (QoL) impact; and Integrate QoL assessments into shared decision-making with patients who have moderate to severe AD.
Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer. Presenters: Cristina Saura Manich, MD, PhD Head, Breast Cancer Unit Medical Oncology Service Vall d'Hebron University Hospital Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain Giampaolo Bianchini, MD Associate Professor, Universita Vita-Salute San Raffaele Head, Breast Cancer Group, Department of Medical Oncology Head, Clinical Translational and Immunotherapy Research IRCCS Ospedale San Raffaele Milan, Italy Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion.https://bit.ly/4p6W8gP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Multiple myeloma is the second most common blood cancer in the United States and has long been considered a difficult disease to treat. For decades, treatment options were limited, and survival remained poor. However, the therapeutic landscape has changed dramatically over the past several decades with the introduction of stem cell transplantation, targeted drugs, immunotherapies, and more recently, CAR T-cell therapy and bispecific antibodies. A research paper titled “Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023” was published in Volume 17 of Oncotarget. In this study, the researchers examined how these major treatment advances have coincided with changes in multiple myeloma mortality across the United States over nearly five decades. The study was led by first and corresponding author Navkirat Kahlon from the Mass General Cancer Center at Wentworth-Douglass Hospital in Dover, New Hampshire. Full blog - https://www.oncotarget.org/2026/06/29/targeted-therapies-have-coincided-with-a-dramatic-decline-in-multiple-myeloma-mortality-in-the-united-states/ Paper DOI - https://doi.org/10.18632/oncotarget.28877 Correspondence to - Navkirat Kahlon - nkahlon@mgb.org; (ORCID: https://orcid.org/0000-0003-1115-2029) Abstract video - https://www.youtube.com/watch?v=-TNWkG9FyUo Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28877 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, multiple myeloma, epidemiologic trends, mortality reduction, therapeutic advancements, SEER database To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
#thismorning | From #Vaccines to Targeted #Therapy: The Future of #Cancer #Care | Christina Annunziata, MD, PhD, American Cancer Society | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #wellness
In this podcast, experts Manmeet Ahluwalia, MD, MBA; and Ashley S. Margol, MD, MS; discuss targeted therapies for adult and pediatric low-grade gliomas, pediatric diffuse midline glioma, and adult glioblastoma.
In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages. Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]
Only one in three eligible lung cancer patients receives the targeted therapy they should get.That is not a failure of science.It is a failure of delivery.After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data.Yet too many breakthroughs still fail to reach the bedside.Patients fall through fragmented systems.Data does not move cleanly.Community oncologists are overloaded.Tests are missed, delayed, or misread.Promising assets die in quarterly portfolio reviews.And healthcare systems built for pills, tablets, and chronic disease management are now being asked to deliver personalized medicine at scale.In this SPARK20 highlight episode, Alasdair Milton, PhD, Principal at KPMG and leader of the firm's Precision & Advanced Therapies practice, explains why the future of biopharma will not be decided by science alone.It will be decided by translation.From lab bench to boardroom.From data to decisions.From treatment to prevention.Alasdair brings more than 20 years of experience across life sciences strategy, commercial due diligence, precision medicine, advanced therapies, cell and gene therapy, biopharma M&A, diagnostics, and global healthcare transformation.This conversation moves from the precision medicine delivery crisis to China's biotech acceleration, from AI and organoids to trapped pharma assets, from lifelong wellness to the one skill every future biotech leader needs:The ability to translate complex science into business strategy, capital allocation, and patient impact.What You'll Learn in 22 MinutesWhy only one third of eligible lung cancer patients receive targeted therapy(00:01:53)And why precision medicine still breaks in everyday clinical practice.Why science keeps compounding even when systems fail(00:04:33)Including in vivo CAR-T, functional cures, gene therapy, and antibody-drug conjugates.Why innovation does not move in a straight line(00:05:20)How technologies can look dead for years before suddenly changing the market.Why China's biotech speed matters(00:07:36)How AI, organoids, scale, and execution are changing the global innovation map.Why great science dies inside Big Pharma(00:09:20)And how deprioritized assets can become billion-dollar companies when externalized properly.Why the industry must move from sickness to lifelong wellness(00:10:03)Alasdair's vision for a more proactive, preventive, data-driven healthcare system.Why pharma needs better ways to rescue shelved assets(00:13:06)Including examples such as SpringWorks, Cerevel, and new models for unlocking trapped value.How a 400-person Scottish island shaped Alasdair's worldview(00:15:07)The personal story behind his resilience, discipline, and leadership style.Why careers and companies are never linear(00:17:19)What Alasdair learned after moving to Boston and losing his role within weeks.Why the future belongs to translators(00:20:06)The most valuable skill in biotech: explaining complex science to business leaders, investors, and boards.How to connect with Alasdair Milton and the KPMG Precision & Advanced Therapies team(00:21:47)Quotes to Carry With You
Drs. Mantia and Berg continue their discussion of ESMO 2025 data on HER2‑directed antibody–drug conjugates in urothelial cancer and the importance of routine HER2 testing. They highlight the promising efficacy and manageable toxicity of these agents across disease stages and raise future questions about how best to sequence them.
Featuring proceedings from a live event on January 9, 2026, held adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium and moderated by Dr Samuel J Klempner, including the following topics: Treatment approach for metastatic HER2-negative, claudin 18.2-positive, microsatellite instability-high gastroesophageal (GE) cancer (0:00) Duration of chemotherapy for patients with advanced GE cancers receiving nivolumab/chemotherapy (3:06) Younger patient with metastatic PD-L1-positive gastric cancer (5:29) CME information and select publications
Pediatric thyroid nodules are rare, but their risk of malignancy is significantly higher than in adults, raising the stakes for accurate diagnosis and multidisciplinary management. In this episode of the BackTable ENT Podcast Dr. Gopi Shah and co-host Dr. Jeff Hyzer interview Dr. Wen Jiang, pediatric otolaryngologist at Rady Children's Hospital in San Diego, for an in-depth discussion on the evaluation and management of thyroid nodules in children. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction 02:27 - Thyroid Nodule Risks and Care Team 06:47 - Age-related Differences in Nodule Presentation and Outcomes08:50 - Initial workup 13:42 - Ultrasound Interpretation16:07 - Lymph Node Mapping and CT19:58 - Incidental Findings24:14 - Role of FNA, Molecular Testing, and Radiofrequency Ablation32:40 - Molecular Testing Results and Counseling 38:04 - Neck Dissection Strategy40:44 - Hypocalcemia Protocol Considerations44:01 - Parathyroid and Recurrent Laryngeal Nerve Dissection Tips 47:33 - Postop Care and Follow-up 51:25 - Using Radioactive Iodine and Targeted Therapy 54:55 - AI's and Ultrasound and Final Thoughts --- More about this episode Dr. Jiang highlights the key differences between pediatric and adult thyroid nodules. She describes her multidisciplinary approach including collaboration with radiology, pathology, endocrinology and nuclear medicine. The discussion reviews the initial workup for pediatric thyroid nodules and why ultrasound remains the primary diagnostic tool. She also discusses situations where CT with contrast can be helpful for surgical planning. This episode explores the growing role of reflex molecular testing in guiding management decisions and outlines the impacts of molecular testing results. Dr. Jiang shares her approach to patient counseling along with management of calcium and PTH after surgery. The conversation concludes with emerging applications of molecular diagnostics and AI models for improving thyroid ultrasound interpretation. --- Resources Dr. Jiang's Research on Pediatric Thyroid Nodule Management - https://pubmed.ncbi.nlm.nih.gov/26770219/ Bethesda System for Thyroid Cytopathology - https://pmc.ncbi.nlm.nih.gov/articles/PMC7182964/ --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
We're going to cure cancer in our lifetime." It's a rallying cry at every charity event, every fundraiser, every race. But what does that actually mean?Dr. Sonal Gandhi, a medical oncologist, joins Ditch the Labcoat to break down what most people don't understand: we already cure cancer. All the time. Early stage cancers like breast, colon, and skin cancer caught in time have cure rates approaching 90 to 100 percent.The challenge is stage four cancer. Metastatic disease. Cancer that has spread to other organs. And even there, the conversation is shifting. Cancer is increasingly becoming a chronic illness. People are living longer with it, sometimes dying with it rather than from it, just like they do with heart disease or diabetes.Dr. Gandhi walks through what "curing cancer" really means, how treatment has evolved beyond chemotherapy into targeted therapies and immunotherapy, and why prevention matters. Up to 40 percent of cancers are related to modifiable lifestyle factors: smoking, alcohol, obesity, lack of exercise. But even doing everything right doesn't guarantee you won't get cancer. Age is the number one risk factor, and we can't modify that.She also challenges the guilt people carry when they're diagnosed and reframes the fear around the "C word." Maybe it's time to pull cancer back into the middle with the menu of other chronic illnesses we manage, not cure.If you've ever wondered what "curing cancer" actually means, why some cancers are more treatable than others, or what you can do to reduce your risk, this episode will reframe how you think about one of medicine's most feared diagnoses.If you've ever wondered why so many people have unexplained symptoms, why standard treatments fail them, or what actually works when medicine runs out of answers, this episode will reframe how you see chronic illness.Dr. Sonal Gandhi's LinkedinEpisode Takeaways1. We already cure cancer. Early stage cancers (stage 1 or 2) caught in time have cure rates approaching 90 to 100 percent, depending on the type.2. Cancer is not one disease. It's dozens of diseases with different stages, treatments, and outcomes. We're better at treating some than others.3. Stage four (metastatic) cancer is increasingly becoming a chronic illness. Treatments help people live longer with cancer, sometimes dying with it rather than from it.4. Up to 40 percent of cancers are related to modifiable lifestyle factors: smoking, alcohol, obesity, and lack of exercise. Being a healthy weight matters for cancer prevention.5. Age is the number one risk factor for cancer. Every decade you get older, cells get worse at repairing mistakes. We can't modify aging.6. Only 10 to 20 percent of cancers are due to inherited genes. Most cancers happen because of the complicated interplay between lifestyle, environment, and cellular aging.7. Immunotherapy works by preventing cancer cells from turning off the immune system, but it can cause severe autoimmune side effects that need rapid treatment.8. Whole body scans and experimental blood tests sound appealing, but they often create more harm than good. Screening needs to be done in context with clear downstream action plans.Episode Timestamps03:51 – What Does "Curing Cancer" Actually Mean?08:15 – Early Stage vs. Late Stage Cancer: The Critical Difference12:42 – How Chemotherapy, Targeted Therapy, and Immunotherapy Work18:35 – Prevention: Lifestyle Factors That Reduce Cancer Risk21:50 – Why Immunotherapy Can Cause Severe Side Effects30:48 – Cancer as a Chronic Illness, Not a Death Sentence38:22 – Environmental and Occupational Cancer Risks45:51 – Why Whole Body Scans Aren't the AnswerDISCLAMER >>>>>> The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions. >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests. Disclosures: Ditch The Lab Coat podcast is produced by (soundsdebatable.com) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is buzzing with significant shifts driven by scientific advancements, strategic acquisitions, and regulatory changes. A noteworthy transaction is Bayer's $2.4 billion acquisition of Perfuse, aimed at gaining control over an eye disease implant that has shown promising results in phase 2 trials. This acquisition speaks to Bayer's commitment to expanding its ophthalmology portfolio, a field with substantial unmet medical needs due to aging populations. The move highlights how companies are investing heavily in areas expected to see growing patient demand. In the realm of artificial intelligence, Recursion Pharmaceuticals is undergoing a strategic transformation under new leadership. After a decade of AI-driven research without yielding tangible products, the focus is shifting towards translating AI's potential into viable therapeutic solutions. This reflects a broader industry trend where the promise of AI must be balanced with pragmatic strategies to ensure commercial success. Novo Nordisk is making strides with its GLP-1/amylin combo treatment Cagrisema, maintaining its launch plans despite technical setbacks with a single-chamber device design. This demonstrates the company's adaptability in overcoming hurdles to bring innovative diabetes treatments to market, crucial in the competitive landscape of diabetes care. Additionally, Novo Nordisk's obesity treatment Wegovy has posted impressive quarterly revenues of $355 million thanks to strategic pricing and timely market entry ahead of competitors like Eli Lilly in the emerging oral obesity therapy segment. Such success suggests potential redefinition of market dynamics in obesity treatments. GlaxoSmithKline has entered into a $1 billion agreement with China's Siranbio for an oligonucleotide therapy targeting abdominal fat reduction. This partnership highlights GSK's strategic focus on cardiometabolic diseases through nucleic acid-based therapies, which offer high specificity and efficacy. Such therapeutics are becoming increasingly attractive for investment due to their potential impact on diverse health conditions. CellCentric's successful Series D funding round, raising $220 million for its myeloma drug, positions it well for pursuing clinical milestones independently. This signifies a shift towards self-reliant biotech models, illustrating how smaller companies are increasingly able to navigate the drug development landscape without traditional pharma partnerships. Gilead's acquisition of Arcellx for $7.8 billion and its subsequent workforce consolidation reflect ongoing realignments within the CAR-T therapy space. These consolidations indicate strategic prioritization within large biopharmaceutical companies to streamline operations while focusing on promising therapeutic areas like CAR-T cells. In corporate restructuring news, Gilead Sciences announced workforce reductions following its acquisition of Arcellx. While aimed at optimizing operations post-acquisition, it raises concerns about job security amid increasing merger activities within the biotech sector. Avalo's promising phase 2 results in skin disease treatment have renewed interest despite challenges from placebo comparisons. This emphasizes the competitive dynamics and high stakes in dermatological drug development, where even modest efficacy signals can significantly drive market activity. BioCryst's decision to halt its diabetic macular edema program to concentrate on rare diseases exemplifies a strategic pivot towards niche markets with potentially higher returns and less competition. This aligns with broader industry trends emphasizing precision medicine and targeted therapies. Eli Lilly's substantial $4.5 billion investment into its Indiana manufacturing complex underscores a commiSupport the show
BUFFALO, NY – May 6, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on May 4, 2026, titled “Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report.” The study was led by first author Cameron B. Speyer from the UCLA David Geffen School of Medicine, and corresponding author Joseph G. Crompton, who holds appointments at both the UCLA David Geffen School of Medicine and the Jonsson Comprehensive Cancer Center. In this report, the authors describe a rare and clinically informative case of a small bowel gastrointestinal stromal tumor (GIST) harboring two genetic alterations that are typically considered mutually exclusive. GISTs are most commonly driven by activating mutations in the KIT or PDGFRA genes, which confer sensitivity to targeted therapies such as imatinib. In contrast, tumors associated with succinate dehydrogenase (SDH) deficiency represent a distinct subgroup that is generally resistant to these treatments. The patient, a 68-year-old man, presented with progressive abdominal pain, bloating, and constipation. Imaging studies revealed a large heterogeneous mass in the lower abdomen measuring up to 18 cm. A biopsy confirmed a spindle cell neoplasm consistent with GIST, with immunohistochemical staining positive for CD117 and DOG1. Genomic analysis identified both a KIT exon 9 duplication (A502_Y503) and a germline SDHC mutation (p.R50C)—a highly unusual combination. Despite the presence of the SDHC mutation, which is typically associated with resistance to therapy, the patient demonstrated a strong response to high-dose imatinib. After six months of neoadjuvant treatment, imaging showed a marked reduction in tumor size and metabolic activity, enabling successful surgical resection. “This case suggests that oncogenic KIT signaling may remain the dominant driver of GIST behavior despite the presence of a germline SDHC mutation and highlights the importance of integrated molecular interpretation in GIST management.” Pathologic examination of the resected tumor revealed significant treatment response, including extensive necrosis and reduced tumor viability. Notably, immunohistochemistry demonstrated retained SDHB expression, indicating preserved SDH complex function despite the identified germline mutation. The case highlights an important clinical insight: not all detected genetic alterations contribute equally to tumor behavior. While SDH-deficient GISTs are typically resistant to imatinib, this tumor behaved in a manner consistent with KIT-driven disease, underscoring the importance of interpreting molecular findings within their clinical and pathological context. Overall, this report emphasizes the need for integrated molecular analysis in cancer diagnosis and treatment. As next-generation sequencing becomes more widely used, clinicians may encounter tumors with multiple coexisting mutations. Determining the dominant oncogenic driver is essential for selecting the most effective therapy and improving patient outcomes. DOI - https://doi.org/10.18632/oncotarget.28863 Correspondence to - Joseph G. Crompton - jcrompton@mednet.ucla.edu Abstract video - https://www.youtube.com/watch?v=eB_QG2vBNCE Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, GIST, KIT duplication, SDHC mutation, genetic testing, case report To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY – April 29, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on April 28, 2026, titled “Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023.” The study was led by first and corresponding author Navkirat Kahlon from the Mass General Cancer Center at Wentworth-Douglass Hospital, in collaboration with researchers from multiple U.S. institutions. In this study, the researchers examined how mortality trends in multiple myeloma have changed in the United States over nearly five decades, using population-level data from the SEER database. Multiple myeloma, a cancer of plasma cells, has historically been associated with poor survival outcomes, but treatment options have evolved dramatically over time. The analysis revealed a clear shift in mortality trends that closely parallels major therapeutic advances. Between 1975 and the mid-1990s, mortality rates steadily increased, reflecting the limited effectiveness of early treatments such as alkylating agents and corticosteroids. A turning point emerged in the 1990s with the introduction of autologous stem cell transplantation, which marked the first meaningful improvement in survival outcomes. Over the following years, the development of targeted therapies—including immunomodulatory drugs and proteasome inhibitors—was associated with a more pronounced decline in mortality. These treatments introduced new mechanisms of action, such as immune modulation and enhanced cancer cell apoptosis, significantly improving disease control. More recent years have seen further progress with the introduction of monoclonal antibodies, maintenance therapies, and combination treatment strategies. Notably, the steepest decline in mortality occurred between 2021 and 2023, coinciding with the clinical adoption of advanced immunotherapies such as CAR T-cell therapies and bispecific antibodies. These treatments have shown the ability to induce deep and durable responses, even in heavily pretreated patients. “Our findings highlight the real-world impact of targeted therapies on population-level outcomes and underscore the urgent need for care models that ensure accessibility, affordability, and long-term sustainability in the era of precision oncology.” Importantly, while these therapeutic advances have improved survival, they have also introduced new challenges. Many patients now require long-term treatment, which can be associated with cumulative toxicities and a significant financial burden. In addition, access to these therapies remains uneven, influenced by geographic, socioeconomic, and healthcare system factors. Overall, this study provides a comprehensive, real-world view of how advances in cancer treatment have translated into measurable improvements in survival at the population level. At the same time, it highlights the need to ensure that these benefits are both sustainable and accessible to all patients as the field continues to evolve. DOI - https://doi.org/10.18632/oncotarget.28877 Correspondence to - Navkirat Kahlon - nkahlon@mgb.org; (ORCID: https://orcid.org/0000-0003-1115-2029) Abstract video - https://www.youtube.com/watch?v=-TNWkG9FyUo Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
ReferencesSignal Transduction and Targeted Therapy 2025. 10.216. J Neuroinflammation. 2019; 16: 236. Guerra, DJ. 2026. Unpublished LecturesMozart, WA. 1791. Clarinet Concerto in A Major K.622https://music.youtube.com/watch?v=YT_63UntRJE&si=WdJgqsHUf36yHd_MWelch/McVie/McVie and Kirwan. 1971. Woman of a 1000 years. Fleetwood Mac https://open.spotify.com/track/6aE623nY6WVhgYH9VAFQRr?si=05d6b9bffb3941a6Paige. 1970. Tangerine. Led Zeppelinhttps://open.spotify.com/track/4ywWJqYKOwaVVh9xXARWUS?si=00c587e7946f4179
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56) Biomarker assessment approach and treatment selection (10:50) CME information and select publications
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium. CME information and select publications here.
SHOW NOTES:On this episode host Jonathan Chance talks with guest, Dr. Perter Rossi about Whole Gland vs. Targeted Therapy for prostate cancer. Jonathan and Dr. Rossi discuss: · The difference between treating the whole prostate and just targeting the tumor.· What men should they know about, when choosing a prostate cancer treatment option.· Active surveillance as opposed to immediate treatment for prostate cancer.· How we're moving toward a future - where more men can avoid aggressive treatments· What is focal therapy and brachytherapy for treating prostate cancer Prostate Cancer Aware is grateful to the Jevan and Ruzanna Chimayan Foundation for their generous donation, which helps fuel our podcast and website to raise critical awareness about prostate cancer and the PSA test around the world.Prostate Cancer Aware is a copyrighted production. No content maybe rebroadcast or reproduced without the expressed written consent of the Friedman Sidrow Foundation. For more information about prostate cancer, the PSA test, men's health and Jonathan's inspiring new book Unaware, which is about his battle with prostate cancer.Visit our website at: https://www.iknowmypsa.orgEmail us at: https://www.iknowmypsa.org/contactus/Follow Prostate Cancer Aware on social media at:Facebook - https://www.facebook.com/iknowmypsa Twitter - https://twitter.com/iknowmypsa or @iknowmypsaThank you for listening! Remember, Stay Aware and Stay Healthy.™
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WFA865. CME/NCPD/AAPA credit will be available until April 16, 2027.Adapting to Innovation in B-Cell Cancers: Advances With Targeted Therapy & CAR-T and Revisiting the Role of Transplant In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca and Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
Dr. Robert Rifkin, medical oncologist and hematologist at the University of Colorado in Steamboat Springs. He was also a clinical investigator in the trial that led to the approval of BLENREP, a multiple myeloma drug from GSK. Multiple myeloma is the second most common blood cancer, and while the prognosis has dramatically improved, BLENREP is a novel treatment for patients whose disease has relapsed after other therapies. It is the first drug antibody conjugate approved for relapsed multiple myeloma, targeting the BCMA antigen, which is present on nearly all myeloma cells. Robert explains, "This is a condition that is really what I would call a disease of the Medicare population. So the median age of diagnosis is often early 60s, but occasionally you do see the younger patients with more aggressive disease. It's thought that African Americans who contract myeloma also may have a more virulent form of the disease." "Right now we live in a great day and age where we have a tremendous number of good treatments, both upfront, which we really won't be discussing today. And then in patients that have unfortunately relapsed and failed other lines of therapy, that's where the exciting new drug BLENREP comes into play. It's going to have a very specific slot in the myeloma armamentarium." "So BLENREP is unique in that it targets something on the myeloma cells called the BCMA target or B-cell maturation antigen target. That's expressed in 98% of patients with myeloma. So it provides a really great target to shoot at, if you will. Right now, we really have sort of three main classes of therapy to go after it: CAR T-cells and bispecific antibodies that your audience will likely be familiar with. This one is unique in that it's the first drug antibody conjugate approved to treat myeloma. So it's not a cellular therapy, but instead it's a molecule that has the BCMA that binds to the myeloma cells, and then it unloads a payload to kill the myeloma cells. So that's nice. You don't have to go to a huge center with experience in cellular therapies. It can be done readily in the community." #MultipleMyeloma #Oncology #BLENREP #BloodCancer #Belamaf #CancerResearch #Hematology #ClinicalTrials #PrecisionMedicine #CancerTreatment #MedicalAdvancement blenrephcp.com Download the transcript here
Dr. Robert Rifkin, medical oncologist and hematologist at the University of Colorado in Steamboat Springs. He was also a clinical investigator in the trial that led to the approval of BLENREP, a multiple myeloma drug from GSK. Multiple myeloma is the second most common blood cancer, and while the prognosis has dramatically improved, BLENREP is a novel treatment for patients whose disease has relapsed after other therapies. It is the first drug antibody conjugate approved for relapsed multiple myeloma, targeting the BCMA antigen, which is present on nearly all myeloma cells. Robert explains, "This is a condition that is really what I would call a disease of the Medicare population. So the median age of diagnosis is often early 60s, but occasionally you do see the younger patients with more aggressive disease. It's thought that African Americans who contract myeloma also may have a more virulent form of the disease." "Right now we live in a great day and age where we have a tremendous number of good treatments, both upfront, which we really won't be discussing today. And then in patients that have unfortunately relapsed and failed other lines of therapy, that's where the exciting new drug BLENREP comes into play. It's going to have a very specific slot in the myeloma armamentarium." "So BLENREP is unique in that it targets something on the myeloma cells called the BCMA target or B-cell maturation antigen target. That's expressed in 98% of patients with myeloma. So it provides a really great target to shoot at, if you will. Right now, we really have sort of three main classes of therapy to go after it: CAR T-cells and bispecific antibodies that your audience will likely be familiar with. This one is unique in that it's the first drug antibody conjugate approved to treat myeloma. So it's not a cellular therapy, but instead it's a molecule that has the BCMA that binds to the myeloma cells, and then it unloads a payload to kill the myeloma cells. So that's nice. You don't have to go to a huge center with experience in cellular therapies. It can be done readily in the community." #MultipleMyeloma #Oncology #BLENREP #BloodCancer #Belamaf #CancerResearch #Hematology #ClinicalTrials #PrecisionMedicine #CancerTreatment #MedicalAdvancement blenrephcp.com Listen to the podcast here
Stop applying to medical sales jobs online. You're doing it wrong.In this episode of Medical Sales U, I sit down with Todd Ford, National Sales Director at Guardant Health, to pull back the curtain on what it actually takes to lead and land a role in the high-stakes world of precision medicine and oncology diagnostics.Todd has hired over 150+ people at Guardant alone, and his data is clear: only 1 in 65 successful hires comes from an online application. So, how do you get in? We break down the "networking secret," the evolution of genomic testing (NGS), and the daily habits of the top 10% of sales reps who win President's Club year after year.In this episode, you'll learn:Why B2B sales (like copiers) is the ultimate stepping stone to Medical Sales.The "hidden" criteria Todd uses to hire D1 athletes and top-tier talent.How Precision Medicine shifted from Chemotherapy to Targeted Therapy.The reality of "The Hustle": Managing 160 flights a year while raising a family.Why your resume is the least important part of your job search.TIMESTAMPS:0:00 - Introduction: Meet Todd Ford of Guardant Health2:15 - The 10-Year Evolution: From Chemo to Precision Medicine4:40 - Career Roots: Why a Mentor told Todd to sell Copiers first7:00 - Scaling the MRD (Minimal Residual Disease) Team9:30 - How to Move from Sales Rep to National Director12:15 - The "Ante" to get to the table: Consistent Performance15:00 - Hiring Secrets: The "1 in 65" Networking Rule18:30 - Managing the Autonomy: Habits of a Remote Sales Leader21:00 - The Travel Reality: 160 Flights vs. Family Life24:00 - The President's Club: Ritz-Carlton Yachts & Rewards28:00 - Final Advice: Why Initiative is your best Interview ToolCONNECT WITH THE GUEST:Todd Ford on LinkedIn: https://www.linkedin.com/in/todd-ford-914b34/Guardant Health: https://guardanthealth.com/ABOUT MEDICAL SALES U:We help aspiring and veteran sales professionals break into and level up within the medical device, pharmaceutical, and diagnostic industries. Subscribe for weekly interviews with the leaders shaping the future of medicine. We help professionals transition into top-tier medical sales roles: medicalsalesu.com/#MedicalSales #PrecisionMedicine #Oncology #GuardantHealth #SalesLeadership #MedicalDeviceSales #JobSearchTips #PresidentClub #SalesHabits
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Older patient with metastatic claudin 18.2-positive gastroesophageal (GE) cancer (0:00) Management of nausea and vomiting with zolbetuximab for GE cancer (9:37) Younger patient with metastatic claudin 18.2-positive, PD-L1-positive GE cancer (15:34) CME information and select publications
In this podcast, experts Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; and Banu Arun, MD, FASCO; discuss how genetic testing drives breast cancer management from screening and surgical decisions to targeted systemic therapies.
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.
HER2-Positive Biliary Tract Cancer: Biomarkers, Targeted Therapy, and Managed Care Access On this episode, Jeffrey Dunn, PharmD, MBA, President and CEO of Cooperative Benefits Group, discusses the rapidly evolving treatment landscape for HER2-positive biliary tract cancer (BTC) and its implications for managed care. The discussion covers the importance of biomarker testing and molecular profiling in guiding targeted therapy, key NCCN guideline considerations across lines of treatment, and the clinical and economic impact of timely access to HER2-directed therapies. We also discuss payer-provider collaboration strategies to improve testing, coverage alignment, and patient access in this rare and aggressive form of cancer. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Younger patient with metastatic HER2-positive, PD-L1-positive gastric cancer (0:00) Older patient with metastatic HER2-positive gastroesophageal (GE) cancer (8:13) Clinical applications for zanidatamab in GE cancer (13:58) CME information and select publications
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.
Undifferentiated Pleomorphic Sarcomas are one of the most common sarcomas. This class of tumors are aggressive with a risk of local recurrence and distant metastasis. We discuss the presentation, diagnostic challenges, and management of these sarcomas. Bennett C, Bharadwaj S, Arndt A, Chawla A. A systematic review of undifferentiated pleomorphic sarcoma of the chest wall. Chin Clin Oncol. 2023 Dec;12(6):66. Lesovaya EA, Fetisov TI, Bokhyan BY, Senchenko MA, Rogozhin DV, Maksimova VP, Demko AN, Belitsky GA, Yakubovskaya MG, Kirsanov KI. Genetic Heterogeneity of Undifferentiated Pleomorphic Sarcoma: Is There Potential for Targeted Therapy? Cancers (Basel). 2025 Nov 10;17(22):3613 Sun H, Liu J, Hu F, Xu M, Leng A, Jiang F, Chen K. Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma. Front Genet. 2023 Feb 16;14:1109491 xFind out More about our Doctors: Dr. Izuchukwu Ibe: www.linkedin.com/in/izuchukwu-ibe-a073537a/ Dr. Elyse Brinkmann: www.linkedin.com/in/elyse-brinkmann/
© 2020-2026 Ivy Podcast Discovery LLC
